RxDoctor Payments Data

Gene Tran, DO

Neurology · Valencia, CANPI 1003094046

Payments from drug & device makers

$35,570in general payments, 2019–2025

Across 187 payments — averaging $190.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$24K
  • Teva Pharmaceuticals USA, Inc.$8K
  • Amgen$750
  • EMD Serono, Inc.$608
  • Abbott$253
  • Harmony Biosciences LLC$194
  • plus $902 from 11 others

What the payments were for

  • Speaking & faculty fees$29,70884%
  • Food & beverage$5,61816%
  • Education$2441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,570 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$78,656
Medicare patients
231
Services billed
3,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dalfampridine ErDalfampridine16$30,837
Aimovig AutoinjectorErenumab-Aooe21$27,783
Nurtec OdtRimegepant Sulfate15$16,312
EliquisApixaban23$15,795
UbrelvyUbrogepant11$13,070
Memantine Hcl391$10,962
Quetiapine Fumarate201$8,394
Donepezil Hcl423$7,273
Carbidopa-LevodopaCarbidopa/Levodopa156$6,837
Levetiracetam152$6,101
Ropinirole Hcl163$5,513
Carbidopa-Levodopa ErCarbidopa/Levodopa53$4,836
Entacapone15$4,450
Rasagiline Mesylate25$3,953
Gabapentin134$3,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$79$32,10738 claims
AbbVieUbrelvy$24,411$13,07011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →